Sunil V Badve

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8267617/publications.pdf

Version: 2024-02-01

124	4,517	101543	123424
papers	citations	36 h-index	61 g-index

127	127	127	5215
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Comparison of Clinical Outcomes and Adverse Events Associated With Glucose-Lowering Drugs in Patients With Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2016, 316, 313.	7.4	329
2	Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ, The, 2021, 372, m4573.	6.0	322
3	Effects of Allopurinol on the Progression of Chronic Kidney Disease. New England Journal of Medicine, 2020, 382, 2504-2513.	27.0	281
4	Recent Peritonitis Associates with Mortality among Patients Treated with Peritoneal Dialysis. Journal of the American Society of Nephrology: JASN, 2012, 23, 1398-1405.	6.1	198
5	Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis. Nephrology Dialysis Transplantation, 2014, 29, 406-413.	0.7	191
6	Effects of Beta-Adrenergic Antagonists in Patients With Chronic Kidney Disease. Journal of the American College of Cardiology, 2011, 58, 1152-1161.	2.8	148
7	Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease. Annals of Internal Medicine, 2019, 171, 181.	3.9	108
8	Multicenter Registry Analysis of Center Characteristics Associated with Technique Failure in Patients on Incident Peritoneal Dialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1090-1099.	4.5	94
9	Biocompatible dialysis fluids for peritoneal dialysis. The Cochrane Library, 2014, , CD007554.	2.8	85
10	Risk Predictors and Causes of Technique Failure Within the First Year of Peritoneal Dialysis: An Australia and New Zealand Dialysis and Transplant Registry (ANZDATA) Study. American Journal of Kidney Diseases, 2018, 72, 188-197.	1.9	85
11	Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrology Dialysis Transplantation, 2010, 25, 1973-1979.	0.7	84
12	Effect of Fish Oil Supplementation and Aspirin Use on Arteriovenous Fistula Failure in Patients Requiring Hemodialysis. JAMA Internal Medicine, 2017, 177, 184.	5.1	77
13	Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial. Lancet Infectious Diseases, The, 2014, 14, 23-30.	9.1	76
14	Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. Nephrology Dialysis Transplantation, 2013, 28, 1899-1907.	0.7	75
15	The impact of neutral-pH peritoneal dialysates with reduced glucose degradation products on clinical outcomes in peritoneal dialysis patients. Kidney International, 2013, 84, 969-979.	5.2	73
16	Duration of Hemodialysis following Peritoneal Dialysis Cessation in Australia and New Zealand: Proposal for a Standardized Definition of Technique Failure. Peritoneal Dialysis International, 2016, 36, 623-630.	2.3	71
17	Automated and continuous ambulatory peritoneal dialysis have similar outcomes. Kidney International, 2008, 73, 480-488.	5.2	68
18	Center Effects and Peritoneal Dialysis Peritonitis Outcomes: Analysis of a National Registry. American Journal of Kidney Diseases, 2018, 71, 814-821.	1.9	66

#	Article	IF	Citations
19	Relapsing and Recurrent Peritoneal Dialysisâ€“Associated Peritonitis: A Multicenter Registry Study. American Journal of Kidney Diseases, 2011, 58, 429-436.	1.9	63
20	Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD). BMJ Open, 2018, 8, e018794.	1.9	60
21	Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney International, 2013, 83, 503-510.	5.2	59
22	Center-Specific Factors Associated with Peritonitis Riskâ€”A Multi-Center Registry Analysis. Peritoneal Dialysis International, 2016, 36, 509-518.	2.3	54
23	A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD). Journal of the American Society of Nephrology: JASN, 2020, 31, 2653-2666.	6.1	52
24	The Validity of Left Ventricular Mass as a Surrogate End Point for All-Cause and Cardiovascular Mortality Outcomes in People With CKD: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2016, 68, 554-563.	1.9	51
25	The Association between Peritoneal Dialysis Modality and Peritonitis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1091-1097.	4.5	49
26	Daily Variation in Death in Patients Treated by Long-term Dialysis: Comparison of In-Center Hemodialysis to Peritoneal and Home Hemodialysis. American Journal of Kidney Diseases, 2013, 61, 96-103.	1.9	48
27	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. The Cochrane Library, 2018, 9, CD011798.	2.8	48
28	Challenges of conducting a trial of uric-acid-lowering therapy in CKD. Nature Reviews Nephrology, 2011, 7, 295-300.	9.6	46
29	Biocompatible dialysis fluids for peritoneal dialysis. The Cochrane Library, 2018, 2018, CD007554.	2.8	46
30	Long-term outcomes of end-stage kidney disease for patients with lupus nephritis. Kidney International, 2016, 89, 1337-1345.	5.2	44
31	The Outcomes of Patients with ESRD and ANCA-Associated Vasculitis in Australia and New Zealand. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 773-780.	4.5	43
32	Phosphate in early chronic kidney disease: Associations with clinical outcomes and a target to reduce cardiovascular risk. Nephrology, 2012, 17, 433-444.	1.6	42
33	Effect of previously failed kidney transplantation on peritoneal dialysis outcomes in the Australian and New Zealand patient populations. Nephrology Dialysis Transplantation, 2006, 21, 776-783.	0.7	41
34	End-stage kidney disease due to Alport syndrome: outcomes in 296 consecutive Australia and New Zealand Dialysis and Transplant Registry cases. Nephrology Dialysis Transplantation, 2014, 29, 2277-2286.	0.7	40
35	Use of aminoglycosides for peritoneal dialysis-associated peritonitis does not affect residual renal function. Nephrology Dialysis Transplantation, 2012, 27, 381-387.	0.7	38
36	The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS Program. Lancet Rheumatology, The, 2019, 1, e220-e228.	3.9	38

#	Article	IF	Citations
37	End-stage renal failure due to amyloidosis: outcomes in 490 ANZDATA registry cases. Nephrology Dialysis Transplantation, 2013, 28, 455-461.	0.7	37
38	The Association between Body Mass Index and Mortality in Incident Dialysis Patients. PLoS ONE, 2014, 9, e114897.	2.5	37
39	The Î²-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial. American Journal of Kidney Diseases, 2016, 67, 902-911.	1.9	36
40	Peritoneal dialysis outcomes after temporary haemodialysis transfer for peritonitis. Nephrology Dialysis Transplantation, 2014, 29, 1940-1947.	0.7	34
41	Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials. Nephrology Dialysis Transplantation, 2016, 31, 1425-1436.	0.7	34
42	A Randomized Controlled Trial of Intravenous or Oral Iron for Posttransplant Anemia in Kidney Transplantation. Transplantation, 2012, 93, 822-826.	1.0	33
43	Effect of Urate-Lowering Therapy on Cardiovascular and Kidney Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 1576-1586.	4.5	33
44	Seasonal variation in peritoneal dialysis-associated peritonitis: a multi-centre registry study. Nephrology Dialysis Transplantation, 2012, 27, 2028-2036.	0.7	31
45	Peritoneal Phosphate Clearance is Influenced by Peritoneal Dialysis Modality, Independent of Peritoneal Transport Characteristics. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1711-1717.	4.5	30
46	Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1845-1855.	4.5	30
47	A Randomized, Placebo-Controlled Trial of Pentoxifylline on Erythropoiesis-Stimulating Agent Hyporesponsiveness in Anemic Patients With CKD: The Handling Erythropoietin Resistance With Oxpentifylline (HERO) Trial. American Journal of Kidney Diseases, 2015, 65, 49-57.	1.9	29
48	Low Serum Potassium Levels and Clinical Outcomes in Peritoneal Dialysisâ€"International Results from PDOPPS. Kidney International Reports, 2021, 6, 313-324.	0.8	29
49	The effects of living distantly from peritoneal dialysis units on peritonitis risk, microbiology, treatment and outcomes: a multi-centre registry study. BMC Nephrology, 2012, 13, 41.	1.8	27
50	Association of Biocompatible Peritoneal Dialysis Solutions with Peritonitis Risk, Treatment, and Outcomes. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1556-1563.	4.5	26
51	End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases. American Journal of Nephrology, 2015, 42, 177-184.	3.1	26
52	Effects of ischaemic conditioning on major clinical outcomes in people undergoing invasive procedures: systematic review and meta-analysis. BMJ, The, 2016, 355, i5599.	6.0	25
53	Multicentre registry data analysis comparing outcomes of culture-negative peritonitis and different subtypes of culture-positive peritonitis in peritoneal dialysis patients. Peritoneal Dialysis International, 2020, 40, 47-56.	2.3	24
54	Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial. American Journal of Nephrology, 2020, 51, 201-215.	3.1	24

#	Article	IF	Citations
55	The Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study: the updated final trial protocol and rationale of post-initiation trial modifications. BMC Nephrology, 2015, 16, 89.	1.8	21
56	Breast Cancer and Transplantation. American Journal of Transplantation, 2017, 17, 2243-2253.	4.7	21
57	A Systematic Review and Meta-Analysis on Effects of Bicarbonate Therapy on Kidney Outcomes. Kidney International Reports, 2021, 6, 695-705.	0.8	21
58	Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. The Cochrane Library, 2017, 2, CD009966.	2.8	20
59	Long-term allograft and patient outcomes of kidney transplant recipients with and without incident cancer - a population cohort study. Oncotarget, 2017, 8, 77771-77782.	1.8	20
60	Repeated Peritoneal Dialysisâ€“Associated Peritonitis: A Multicenter Registry Study. American Journal of Kidney Diseases, 2012, 59, 84-91.	1.9	19
61	The Role of Monitoring Vancomycin Levels in Patients with Peritoneal Dialysis-Associated Peritonitis. Peritoneal Dialysis International, 2015, 35, 222-228.	2.3	19
62	Biocompatible Peritoneal Dialysis Fluids: Clinical Outcomes. International Journal of Nephrology, 2012, 2012, 1-9.	1.3	18
63	Outcomes of Corynebacterium Peritonitis: A Multicenter Registry Analysis. Peritoneal Dialysis International, 2017, 37, 619-626.	2.3	18
64	Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study. BMJ Open, 2019, 9, e024382.	1.9	18
65	Effects of Climatic Region on Peritonitis Risk, Microbiology, Treatment, and Outcomes: A Multicenter Registry Study. Peritoneal Dialysis International, 2013, 33, 75-85.	2.3	17
66	Establishing a clinical trials network in nephrology: experience of the Australasian Kidney Trials Network. Kidney International, 2014, 85, 23-30.	5.2	17
67	Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease. , 2022, 1, .		17
68	Weekend Compared with Weekday Presentations of Peritoneal Dialysisâ€“Associated Peritonitis. Peritoneal Dialysis International, 2012, 32, 516-524.	2.3	16
69	Socio-Economic Status and Peritonitis in Australian Non-Indigenous Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2015, 35, 450-459.	2.3	16
70	Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants. American Journal of Kidney Diseases, 2020, 76, 311-320.	1.9	16
71	Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD. Journal of the American Society of Nephrology: JASN, 2022, 33, 59-76.	6.1	16
72	The Role of Monitoring Gentamicin Levels in Patients with Gram-Negative Peritoneal Dialysis-Associated Peritonitis. Peritoneal Dialysis International, 2014, 34, 219-226.	2.3	14

#	Article	IF	Citations
73	The Effect of Exit-Site Antibacterial Honey versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial. Peritoneal Dialysis International, 2015, 35, 712-721.	2.3	14
74	Association of Socio-Economic Position with Technique Failure and Mortality in Australian Non-Indigenous Peritoneal Dialysis Patients. Peritoneal Dialysis International, 2017, 37, 397-406.	2.3	14
75	Phosphate Balance on Peritoneal Dialysis. Peritoneal Dialysis International, 2008, 28, 26-32.	2.3	13
76	Challenges in Blood Pressure Measurement in Patients Treated With Maintenance Hemodialysis. American Journal of Kidney Diseases, 2012, 60, 463-472.	1.9	13
77	Outcomes of Acinetobacter Peritonitis in Peritoneal Dialysis Patients: A Multicenter Registry Analysis. Peritoneal Dialysis International, 2018, 38, 257-265.	2.3	12
78	Differences in peritoneal dialysis technique survival between patients treated with peritoneal dialysis systems from different companies. Nephrology Dialysis Transplantation, 2019, 34, 1035-1044.	0.7	12
79	The effects of dipeptidyl peptidaseâ€4 inhibitors on kidney outcomes. Diabetes, Obesity and Metabolism, 2021, 23, 763-773.	4.4	12
80	Is the problem with the vehicle or the destination? Does highâ€dose ESA or high haemoglobin contribute to poor outcomes in CKD?. Nephrology, 2011, 16, 144-153.	1.6	11
81	APPETITE PREDICTS INTAKE AND NUTRITIONAL STATUS IN PATIENTS RECEIVING PERITONEAL DIALYSIS. Journal of Renal Care, 2016, 42, 123-131.	1.2	11
82	Association between serum hepcidinâ€25 and primary resistance to erythropoiesisâ€stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial. Nephrology, 2017, 22, 548-554.	1.6	11
83	EARLY PERITONITIS AND ITS OUTCOME IN INCIDENT PERITONEAL DIALYSIS PATIENTS. Peritoneal Dialysis International, 2017, , pdi.2017.00029.	2.3	11
84	The Risk of Acute Kidney Injury with Oral Anticoagulants in Elderly Adults with Atrial Fibrillation. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1470-1479.	4.5	11
85	Acute renal tubular injury with acute hepatitis A infection: Is it just a coincidence?. Nephrology, 2004, 9, 44-46.	1.6	10
86	Baseline characteristics of the omegaâ€3 fatty acids (<scp>F</scp>ish oils) and <scp>A</scp>spirin in <scp>V</scp>ascular access <scp>OU</scp>tcomes in <scp>RE</scp>nal <scp>D</scp>isease (<scp>FAVOURED</scp>) study. Nephrology, 2016, 21, 217-228.	1.6	10
87	The Honeypot Randomized Controlled Trial Statistical Analysis Plan. Peritoneal Dialysis International, 2013, 33, 426-435.	2.3	9
88	Urate-Lowering Therapy for Preventing Kidney Disease Progression: Are We There Yet?. American Journal of Kidney Diseases, 2018, 72, 776-778.	1.9	9
89	The Relationship between Body Mass Index and Organism-Specific Peritonitis. Peritoneal Dialysis International, 2018, 38, 206-214.	2.3	9
90	Adherence to guideline recommendations for infection prophylaxis in peritoneal dialysis patients. CKJ: Clinical Kidney Journal, 2009, 2, 508-508.	2.9	8

#	Article	IF	Citations
91	Association between Serum Alkaline Phosphatase and Primary Resistance to Erythropoiesis Stimulating Agents in Chronic Kidney Disease: A Secondary Analysis of the HERO Trial. Canadian Journal of Kidney Health and Disease, 2015, 2, 66.	1.1	8
92	The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial. Redox Report, 2016, 21, 14-23.	4.5	8
93	Longâ€term outcomes of endâ€stage kidney disease for patients with <scp>IgA</scp> nephropathy: A multiâ€centre registry study. Nephrology, 2016, 21, 387-396.	1.6	8
94	Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial. PLoS ONE, 2019, 14, e0213274.	2.5	8
95	Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis. Journal of Nephrology, 2022, 35, 1159-1170.	2.0	8
96	Frequent versus Standard Hemodialysis. New England Journal of Medicine, 2011, 364, 974-976.	27.0	7
97	End-stage kidney disease due to haemolytic uraemic syndrome â€“ outcomes in 241 consecutive ANZDATA registry cases. BMC Nephrology, 2012, 13, 164.	1.8	7
98	Carvedilol and Cardiac Biomarkers in Dialysis Patients: Secondary Analysis of a Randomized Controlled Trial. Kidney and Blood Pressure Research, 2017, 42, 1033-1044.	2.0	7
99	Effect of Dialysis Modality on Survival of Hepatitis C-Infected ESRF Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 2657-2661.	4.5	6
100	Interventions for erythropoietin-resistant anaemia in dialysis patients. The Cochrane Library, 2013, , CD006861.	2.8	6
101	The rationale and design of the <scp>B</scp>etaâ€blocker to <scp>LO</scp>wer <scp>CA</scp>rdiovascular <scp>D</scp>ialysis <scp>E</scp>vents (<scp>BLOCADE</scp>) <scp>F</scp>easibility <scp>S</scp>tudy. Nephrology, 2015, 20, 140-147.	1.6	6
102	Crystalglobulinemia in Multiple Myeloma: A Rare Case Report of Survival and Renal Recovery. Canadian Journal of Kidney Health and Disease, 2020, 7, 205435812092262.	1.1	6
103	Recent evidence on the effect of urate-lowering treatment on the progression of kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 346-352.	2.0	6
104	Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease. The Cochrane Library, 0, , .	2.8	5
105	Sex differences in chronic kidney disease prevalence in Asia: a systematic review and meta-analysis. CKJ: Clinical Kidney Journal, 2022, 15, 1144-1151.	2.9	5
106	Recent evidence for direct oral anticoagulants in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2019, 28, 251-261.	2.0	4
107	Icodextrin use for peritoneal dialysis in Australia: A cohort study using Australia and New Zealand Dialysis and Transplant Registry. Peritoneal Dialysis International, 2020, 40, 209-219.	2.3	4
108	Relationship Between Dietary Phosphate Intake and Biomarkers of Bone and Mineral Metabolism in Australian Adults With Chronic Kidney Disease. , 2022, 32, 58-67.		4

#	Article	IF	Citations
109	International Icodextrin Use and association with peritoneal membrane function, fluid removal, patient and technique survival. Kidney360, 0, , 10.34067/KID.0006922021.	2.1	4
110	Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. Nephrology, 2017, 22, 823-824.	1.6	3
111	Representativeness of Honeypot Trial Participants to Australasian PD Patients. Peritoneal Dialysis International, 2017, 37, 516-522.	2.3	3
112	Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the <scp>ADVANCE</scp> trial. Diabetes, Obesity and Metabolism, 2021, 23, 1420-1425.	4.4	3
113	Recent evidence on the effect of treatment of metabolic acid on the progression of kidney disease. Current Opinion in Nephrology and Hypertension, 2021, 30, 467-473.	2.0	3
114	Haemodialysis catheter care in practice. Nature Reviews Nephrology, 2014, 10, 131-133.	9.6	2
115	A nephrology guide to reading and using systematic reviews of randomized trials. Nephrology Dialysis Transplantation, 2015, 30, 878-884.	0.7	2
116	Daily Home Hemodialysis: Balancing Cardiovascular Benefits With Infectious Harms. American Journal of Kidney Diseases, 2015, 65, 6-8.	1.9	2
117	Dietary Phosphate Consumption in Australians With Stages 3b and 4 Chronic Kidney Disease. , 2021, 31, 155-163.		2
118	Representativeness of the PDOPPS cohort compared to the Australian PD population. Peritoneal Dialysis International, 2022, 42, 403-414.	2.3	2
119	A comparison of arteriovenous fistula failure between Malaysian and Australian and New Zealand participants enrolled in the FAVOURED trial. Journal of Vascular Access, 2024, 25, 193-202.	0.9	2
120	Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers. Journal of the American Society of Nephrology: JASN, 2019, 30, 909-910.	6.1	1
121	Assessment of Dietary Sodium Intake Using the Scored Salt Questionnaire in Autosomal Dominant Polycystic Kidney Disease. Nutrients, 2020, 12, 3376.	4.1	1
122	Does Sevelamer reduce mortality by slowing of progression of coronary calcification?. Kidney International, 2007, 71, 1328-1329.	5.2	0
123	Editor's note. Internal Medicine Journal, 2021, 51, 1368-1368.	0.8	0
124	Treatment preferences for primary membranous nephropathy: Results of a multinational survey among nephrologists in the South Asia Pacific region. Nephrology, 2021, , .	1.6	0